Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis.

ABSTRACT:

Background

To evaluate the overall satisfaction, device usability, and injection experience of MS patients self-administering ofatumumab using the Sensoready^® autoinjector device in the United States (US).

Methods

This US-based, cross-sectional survey study included patients with MS (≥ 18 years) who self-administered ofatumumab using the Sensoready device within the previous 12 months of the survey. Eligible patients were administered a 30-item de novo questionnaire that focused on overall device satisfaction, device usability, convenience/flexibility for travel with the device, user confidence, injection experience, and time to administer the injection. Ratings were measured on Likert and numeric rating scales, with higher scores indicating positive responses.

SUBMITTER: Ross AP 

PROVIDER: S-EPMC11744959 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature